Abdullah Golbol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdullah Golbol has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Rıza Şahin
Kahramanmaras Sutcu Imam Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Kahramanmaras, Turkey
1 shared publication - Ahmet Şahin
Department of Infectious Diseases and Clinical Microbiology, Gaziantep Islam Science and Technology University, Gaziantep, Türkiye
1 shared publication - Akkan Avci
Department of Emergency Medicine, Adana City Research and Training Hospital, University of Health Sciences, Adana 01230, Turkey
1 shared publication - Ali Asan
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Bursa High Specialization Training and Research Hospital, Bursa, Türkiye
1 shared publication - Alpay Azap
Department of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, Turkey
1 shared publication - Asiye Bahar Kaçmaz
Department of Infection Diseases and Clinical Microbiology, American Hospital, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 16 December 2025
- Published by Science Publishing Group in International Journal of Infectious Diseases and Therapy
- Vol. 10 (4) , 68-84
Current Clinical Applications of Entecavir in Hepatitis B Viruses Infection
Entecavir (ETV) is a guanosine nucleoside analogue widely used in the management of chronic Hepatitis B Virus (HBV) infection. It demonstrates consistent antiviral activity, favourable tolerability, and a high genetic barrier to resistance, making it a reliable option across diverse clinical settings. Evidence from clinical trials and real-world studies confirms that ETV achieves sustained viral suppression, alanine aminotransferase (ALT) normalization, and histological improvement, contributing to reduced long-term risks of cirrhosis and hepatocellular carcinoma. Its pharmacokinetic properties and antiviral effectiveness have been established in both treatment-naïve and lamivudine-resistant patients. ETV maintains clinical utility in various special populations, including individuals with decompensated cirrhosis, chronic kidney disease, post-transplant status, and those receiving immunosuppressive therapy. In these groups, ETV retains efficacy with limited drug-drug interactions and a generally mild adverse-event profile. Optimal adherence to therapy remains essential to ensure sustained viral suppression and minimize the risk of treatment failure. In addition to established clinical roles, emerging research has explored new formulations and potential therapeutic applications of ETV, including long-acting delivery strategies and its possible relevance in oncologic contexts. These developments highlight continued interest in optimizing the use of ETV in HBV management. Overall, ETV remains a well-supported antiviral agent that combines durable efficacy, safety, and broad applicability in the treatment of chronic HBV infection.
- 16 December 2025
- Published by Science Publishing Group in International Journal of Infectious Diseases and Therapy
- Vol. 10 (4) , 68-84
Open AccessCurrent Clinical Applications of Entecavir in Hepatitis B Viruses Infection
Entecavir (ETV) is a guanosine nucleoside analogue widely used in the management of chronic Hepatitis B Virus (HBV) infection. It demonstrates consistent antiviral activity, favourable tolerability, and a high genetic barrier to resistance, making it a reliable option across diverse clinical settings. Evidence from clinical trials and real-world studies confirms that ETV achieves sustained viral suppression, alanine aminotransferase (ALT) normalization, and histological improvement, contributing to reduced long-term risks of cirrhosis and hepatocellular carcinoma. Its pharmacokinetic properties and antiviral effectiveness have been established in both treatment-naïve and lamivudine-resistant patients. ETV maintains clinical utility in various special populations, including individuals with decompensated cirrhosis, chronic kidney disease, post-transplant status, and those receiving immunosuppressive therapy. In these groups, ETV retains efficacy with limited drug-drug interactions and a generally mild adverse-event profile. Optimal adherence to therapy remains essential to ensure sustained viral suppression and minimize the risk of treatment failure. In addition to established clinical roles, emerging research has explored new formulations and potential therapeutic applications of ETV, including long-acting delivery strategies and its possible relevance in oncologic contexts. These developments highlight continued interest in optimizing the use of ETV in HBV management. Overall, ETV remains a well-supported antiviral agent that combines durable efficacy, safety, and broad applicability in the treatment of chronic HBV infection.
- Open Access
- 25 September 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (3) , 273-282
Impact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye
Healthcare-associated infections (HAIs) are common yet largely preventable through adherence to evidence-based guidelines. In 2005, Türkiye implemented a national infection control program, which led to significant reductions in HAI rates, including a 50% decrease in central line-associated bloodstream infections (CLABSIs) between 2008 and 2017. This result was in parallel with data from
- 25 September 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (3) , 273-282
Open AccessImpact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye
Healthcare-associated infections (HAIs) are common yet largely preventable through adherence to evidence-based guidelines. In 2005, Türkiye implemented a national infection control program, which led to significant reductions in HAI rates, including a 50% decrease in central line-associated bloodstream infections (CLABSIs) between 2008 and 2017. This result was in parallel with data from
- 21 August 2023
- Published by Kare Publishing in Global Emergency and Critical Care
- Vol. 2 (2) , 56-62
Effect of Disease Severity on the Clinical Course, Maternal and Perinatal Outcomes in Pregnancy in COVID-19 Infection
- 21 August 2023
- Published by Kare Publishing in Global Emergency and Critical Care
- Vol. 2 (2) , 56-62
Effect of Disease Severity on the Clinical Course, Maternal and Perinatal Outcomes in Pregnancy in COVID-19 Infection